# Firefly Neuroscience, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Firefly Neuroscience, Inc). ## Overview Firefly Neuroscience, Inc. develops and commercializes the BNA Platform, a brain-health assessment product that combines EEG-based measurement, software, and AI-driven analysis. The company targets neurologists and other healthcare professionals, while also pursuing collaborations with pharmaceutical companies supporting neuroscience drug development. ## Products & services • BNA Platform brain-health assessment software • EEG-based testing and analysis services • Equipment rental for brain activity measurement • Clinical study and research project services • Hardware/software package from Evoke Neuroscience • Per-use and licensing-based clinic commercialization model - **BNA Platform software** (40%) — Core brain-health platform used to assess patients and support clinical decision-making. - **Testing and per-use services** (25%) — BNA testing and usage-based services sold to clinics on a recurring basis. - **Equipment sales and rentals** (20%) — Hardware sales and rentals tied to EEG and brain-activity measurement workflows. - **Clinical studies and projects** (15%) — Contracted research and clinical study work for pharmaceutical and neuroscience partners. - BNA Platform brain-health assessment software - EEG-based testing and analysis services - Equipment rental for brain activity measurement - Clinical study and research project services - Hardware/software package from Evoke Neuroscience - Per-use and licensing-based clinic commercialization model ## Customers The company sells primarily to U.S. neurologists, healthcare professionals, and clinic-based medical practitioners who use the platform for patient assessment and management. It also targets pharmaceutical and neuroscience drug-development companies that need clinical-strategy support, biomarker insights, and study services. Adoption depends on proving clinical utility, workflow fit, and measurable patient-outcome benefits. - **Neurology clinics and practitioners** (primary) — Buy BNA Platform licenses and per-use testing to support diagnosis and patient management. - **Pharmaceutical and biotech companies** (primary) — Buy collaboration services for neuroscience drug development, clinical studies, and strategy support. - **Medical practitioners and healthcare providers** (secondary) — Use the platform in clinical settings to interpret brain function and guide therapy decisions. - **Research and clinical study sponsors** (secondary) — Engage the company for projects that generate data, validate biomarkers, and support trials. - Neurologists and neurology clinics buying BNA Platform access - Healthcare professionals using EEG-based patient assessment tools - Pharmaceutical companies funding neuroscience research collaborations - Drug-development teams seeking clinical strategy and biomarker support - Clinics adopting per-use licensing to improve patient management ## Geography Firefly is headquartered in the United States and its planned commercialization is centered on U.S. neurologists and healthcare professionals. The company’s current disclosures emphasize U.S. market rollout, while pharmaceutical collaborations may extend beyond clinic sales depending on partner needs. Geography matters mainly because regulatory, reimbursement, and adoption dynamics are tied to U.S. clinical practice. - United States is the core commercial market - Clinic rollout is focused on U.S. neurologists and healthcare professionals - Pharma collaborations may be broader than the clinic channel - No country-level revenue disclosure was provided in the excerpts - U.S. market access and clinical adoption are key execution factors ## Strategy The company’s near-term strategy is to commercialize the BNA Platform through targeted outreach, soft launches, and a direct sales effort into strategic clinic accounts. It is also building a second growth path through pharmaceutical collaborations that can generate project-based revenue and expand the clinical evidence base. The Evoke acquisition adds hardware/software capabilities and broadens the product set available for commercialization. - **Commercialize the BNA Platform in clinics** (short-term) — Clinic adoption is the main path to recurring product revenue and market validation. - **Build pharmaceutical collaboration revenue** (medium-term) — Partner projects can fund development, generate data, and support biomarker discovery. - **Integrate Evoke Neuroscience** (medium-term) — The acquisition adds hardware/software capabilities and expands the product portfolio. - Launch and scale the BNA Platform in 2025 - Win neurologist and clinic accounts through targeted outreach - Use soft launches and scientific materials to drive adoption - Expand pharma collaborations to support neuroscience development - Integrate Evoke to broaden hardware/software offerings ## Risks Firefly remains a pre-commercial or early-commercial company, so execution risk around product adoption, sales conversion, and clinical validation is high. It also depends on external financing and may continue to burn cash while it scales the BNA Platform and integrates acquisitions. As a healthcare software and device-adjacent business, it faces regulatory, reimbursement, and competitive risks tied to proving clinical utility. - **Slow commercialization of the BNA Platform** [high] — Revenue depends on convincing clinics and physicians to adopt a new brain-health workflow. - **Ongoing negative operating cash flow** [high] — Management expects continued cash burn while investing in launch and integration. - **Acquisition integration risk** [medium] — Evoke adds hardware/software operations that must be integrated into sales and cost structure. - **Clinical evidence and adoption risk** [high] — The value proposition depends on demonstrating better outcomes and practical utility. - Commercial adoption risk if neurologists do not adopt the platform - Cash burn and financing dependence during commercialization - Integration risk from the Evoke acquisition - Clinical validation risk if outcomes data are insufficient - Regulatory and reimbursement uncertainty in healthcare workflows ## Accounting Investors should watch revenue recognition because the company uses a mix of licensing, per-use fees, equipment sales, rentals, and clinical projects, each of which may be recognized differently. Fair value accounting is also important because the company disclosed derivative fair value changes and warrant-related financing activity, which can create volatility below operating income. Acquisition accounting for Evoke and stock-based or warrant-related transactions may materially affect reported assets, expenses, and equity. - **Revenue recognition across multiple service types** — Can affect quarterly comparability and reported growth - **Derivative fair value measurement** — Can create non-operating earnings volatility - **Business combination accounting for Evoke** — May affect amortization, impairment risk, and balance sheet presentation - **Warrants and equity-linked financing** — Can change share count and financing-related accounting - Mixed revenue streams may have different recognition timing - Per-use fees and clinical projects can create quarter-to-quarter volatility - Derivative fair value changes can swing other income/expense - Acquisition accounting for Evoke affects assets and goodwill/intangibles - Warrants and equity financing can create dilution and valuation effects --- *Last updated: 2026-04-28T20:06:31.209711+00:00*